The German experience in reference pricing

被引:57
作者
Giuliani, G
Selke, G
Garattini, L [1 ]
机构
[1] Mario Negri Inst Pharmacol Res, Ctr Hlth Econ CESAV, I-24020 Ranica, BG, Italy
[2] Wissensch Inst AOK, WIdO, Bonn, Germany
关键词
German health care system; pharmaceutical policy; reference pricing;
D O I
10.1016/S0168-8510(98)00012-8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Price regulation schemes function both as a means for public authorities to contain costs, and as an economic tool to support the national pharmaceutical industry. This twofold contradictory aim of public intervention in pharmaceutical demand and supply makes such pricing schemes difficult to apply. This article concerns the reference price scheme which concerns setting a price cap for each active ingredient, or group of active ingredients considered equivalent according to some feature (e.g. therapeutic effects and chemical structure). In 1989, the reference price scheme for reimbursable drugs was introduced in Germany to reduce pharmaceutical expenditure, which had been steadily increasing in the past. The study investigates the economic effects of introducing reference prices in Germany in order to assess whether this system has been effective in containing public pharmaceutical expenditure. We conclude that the reference price scheme is an effective tool for price control, but cost containment requires further measures. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:73 / 85
页数:13
相关论文
共 18 条
[1]   METHODOLOGICAL ASPECTS OF INTERNATIONAL DRUG PRICE COMPARISONS [J].
ANDERSSON, F .
PHARMACOECONOMICS, 1993, 4 (04) :247-256
[2]  
DEVOS C, 1994, COST CONTAINMENT PRI, P167
[3]   A COMPARATIVE-ANALYSIS OF THE PHARMACEUTICAL MARKET IN 4 EUROPEAN COUNTRIES [J].
GARATTINI, L ;
SALVIONI, F ;
SCOPELLITI, D ;
GARATTINI, S .
PHARMACOECONOMICS, 1994, 6 (05) :417-423
[4]  
GARATTINI L, 1993, METODOLOGIE DETERMIN
[5]  
Gross D J, 1994, Health Care Financ Rev, V15, P127
[6]  
JENSEN A, 1991, REFERENCE PRICE PHAR
[7]  
MACARTHUR D, 1994, PHARM COST CONTAINME
[8]  
MACARTHUR D, 1995, PHARMA PRICING REV, P17
[9]  
MUNNICH FE, 1994, PHARMACOECONOMICS, V6, P22
[10]  
SCHMEINCK W, 1994, COST CONTAINMENT PRI, P161